- Conditions
- CANCER,NOS
- Interventions
- Lirilumab, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 16
- States / cities
- San Francisco, California • Ocala, Florida • Chicago, Illinois + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 17,835
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes, Obesity
- Interventions
- PF-06882961, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Searcy, Arkansas • Montclair, California + 31 more
- Conditions
- Healthy Volunteers
- Interventions
- IW-3300, Placebo
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hepatocellular Carcinoma
- Interventions
- IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Chicago, Illinois + 4 more
- Conditions
- Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
- Interventions
- Antizol, Placebo, Ethanol
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Small Cell Lung Cancer
- Interventions
- ABBV-011, Budigalimab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Sacramento, California + 16 more
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- JBI-802
- Drug
- Lead sponsor
- Jubilant Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Cincinnati, Ohio • Nashville, Tennessee + 1 more
- Conditions
- Cold Agglutinin Disease
- Interventions
- sutimlimab (BIVV009), placebo
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Georgetown, District of Columbia + 10 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- INCB028050, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more
- Conditions
- Head and Neck Cancer
- Interventions
- Cetuximab, 5-FU, Hydroxyurea, Twice-daily radiation, Cisplatin, Accelerated fraction radiotherapy with concomitant boost
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- ODM-201
- Drug
- Lead sponsor
- Orion Corporation, Orion Pharma
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 8
- States / cities
- Wheat Ridge, Colorado • Norwich, Connecticut • Ocala, Florida + 5 more
- Conditions
- Stressor, Individual, Alcohol Impairment, Sleep Deprivation, Impairment, Cognitive
- Interventions
- Alcohol Administration, Sleep Deprivation, Control
- Other · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pain
- Interventions
- Hypertonic Saline, Normal Saline
- Drug · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Pancreas Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer (Unresectable)
- Interventions
- MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells, MT-601 dose 1200 million cells
- Drug
- Lead sponsor
- Marker Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
- Interventions
- Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab
- Radiation · Drug
- Lead sponsor
- Benjamin Spieler
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Non-erosive Reflux Disease
- Interventions
- BLI5100, Placebo
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 788 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 112
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more
- Conditions
- Muscle-invasive Urothelial Cancer of the Bladder
- Interventions
- Pembrolizumab, Transurethral Resection of Bladder Tumor, Gemcitabine, External Beam Radiation Therapy
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more
- Conditions
- Influenza, Seasonal Influenza
- Interventions
- VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Breast Cancer
- Interventions
- Docetaxel, Erythromycin Breath Test (ERMBT)
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Ischemia Reperfusion Injury, Delayed Graft Function
- Interventions
- Treprostinil
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- AZD5991, AZD5991 + Venetoclax
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 10
- States / cities
- Orange, California • Aurora, Colorado • Atlanta, Georgia + 7 more
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Amifampridine Phosphate, Placebo Oral Tablet
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
- Interventions
- Azacitidine, Pevonedistat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • Chapel Hill, North Carolina
- Conditions
- Heart Failure
- Interventions
- CK-1827452, Placebo
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- San Diego, California • Newark, Delaware